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Abstract
Background: Human parainfluenza viruses (HPIVs) are important causes of upper respiratory tract illness (URTI) and
lower respiratory tract illness (LRTI). To analyse epidemiologic and clinical characteristics of the four types of human
parainfluenza viruses (HPIVs), patients with acute respiratory tract illness (ARTI) were studied in Guangzhou, southern
China.
Methods: Throat swabs (n=4755) were collected and tested from children and adults with ARTI over a 26-month
period, and 4447 of 4755 (93.5%) patients’ clinical presentations were recorded for further analysis.
Results: Of 4755 patients tested, 178 (3.7%) were positive for HPIV. Ninety-nine (2.1%) samples were positive for
HPIV-3, 58 (1.2%) for HPIV-1, 19 (0.4%) for HPIV-2 and 8 (0.2%) for HPIV-4. 160/178 (88.9%) HPIV-positive samples
were from paediatric patients younger than 5 years old, but no infant under one month of age was HPIV positive.
Seasonal peaks of HPIV-3 and HPIV-1 occurred as autumn turned to winter and summer turned to autumn. HPIV-2
and HPIV-4 were detected less frequently, and their frequency of isolation increased when the frequency of HPIV-3
and HPIV-1 declined. HPIV infection led to a wide spectrum of symptoms, and more “hoarseness” (p=0.015),
“abnormal pulmonary breathing sound” (p<0.001), “dyspnoea” (p<0.001), “pneumonia” (p=0.01), and “diarrhoea”
(p<0.001) presented in HPIV-positive patients than HPIV-negative patients. 10/10 (100%) HPIV-positive adult patients
(≥14 years old) presented with systemic influenza-like symptoms, while 90/164 (54.9%) HPIV-positive paediatric
patients (<14 years old) presented with these symptoms (p=0.005). The only significant difference in clinical
presentation between HPIV types was “Expectoration” (p<0.001). Co-infections were common, with 33.3%–63.2% of
samples positive for the four HPIV types also testing positive for other respiratory pathogens. However, no
significant differences were seen in clinical presentation between patients solely infected with HPIV and patients
co-infected with HPIV and other respiratory pathogens.
Conclusions: HPIV infection led to a wide spectrum of symptoms, and similar clinical manifestations were found in
the patients with four different types of HPIVs. The study suggested pathogenic activity of HPIV in gastrointestinal
illness. The clinical presentation of HPIV infection may differ by patient age.
Background
Human parainfluenza viruses (HPIVs) are RNA viruses in
the genus Paramyxoviridae. Four HPIV types have been
identified [1,2]. HPIVs are important causes of upper re-
spiratory tract illness (URTI) and lower respiratory tract
illness (LRTI), especially in children [3,4]. An estimated
five million LRTI occur each year in the United States in
children under 5 years old, and HPIVs have been isolated
in up to one third of these infections [5-7]. The HPIV-1,
HPIV-2 and HPIV-3 are second only to respiratory syncyt-
ial virus (RSV) as a cause of hospitalizations (2%–17%) for
acute respiratory infection among children aged younger
than 5 years in the United States [1,8-10].
Compared with studies of HPIV infection in children,
less is known about infections in adults. Most HPIV
infections in adults cause mild upper respiratory tract
symptoms, but the elderly or those with compromised
immune systems are at increased risk for severe HPIV
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infection [1,3,11-13]. Compared with types 1−3, only a
small number of reports have studied HPIV-4 [14-18],
and the lack of epidemiologic data on HPIV-4 prevents a
clear understanding of the full clinical pattern of HPIVs.
In addition, any differences in the clinical presentation
of the four HPIV types are still largely unknown.
The aims of this study were to explore the epidemiologic
features and clinical manifestations of HPIVs and other
common respiratory pathogens in children and adults
with acute respiratory tract illness (ARTI) in Guangzhou,
southern China, and to uncover clues that might help to
establish clinical distinctions between different HPIV types.
Methods
Respiratory sample collection
Samples in this study were taken as part of standard care.
The First Affiliated Hospital of Guangzhou Medical
University Ethics Committee approved the experimental
design and patient involvement in this study. Written
informed consent was obtained from the patient for publi-
cation of this report and any accompanying images.
Throat swab samples were collected from patients with
ARTI (presenting with at least two of the following symp-
toms: cough, pharyngeal discomfort, nasal obstruction,
coryza, sneeze, dyspnoea) at three hospitals in Guangzhou,
southern China between July 2009 and August 2011. The
samples were refrigerated at 2 to 8°C and transported on
ice to State Key Laboratory of Respiratory Diseases and
analysed every working day or stored at −80°C before test-
ing. Over 97 samples were collected and tested during
each month in our study.
Clinical presentations were collected and categorized
retrospectively into the following six groups from the
patients’ medical records using designed presentation
cards: URTI, LRTI, systemic influenza-like symptoms,
gastrointestinal illness, neurologic symptom and others.
Patients with nasal obstruction, coryza, sneeze, cough,
pharyngeal discomfort, or hoarseness were categorized as
having URTI. Patients with pneumonia, bronchopneumo-
nia, increasing lung markings, dyspnoea, or abnormal pul-
monary breath sound were categorized as having LRTI.
Patients with high fever (≥38°C), chills, dizziness, head-
ache, myalgia or debilitation were categorized as having
systemic influenza-like symptoms. Patients with vomiting,
poor appetite, or diarrhoea were categorized as having
gastrointestinal illness. Patients with convulsion were cate-
gorized as having an neurologic symptom. Patients with
other symptoms, including but not limited to rash, were
classified as “others”. Some patients were assigned to
multiple clinical presentation groups. Pneumonia and
bronchopneumonia were diagnosed by chest radiography.
Pneumonia was defined as an acute illness with radio-
graphic pulmonary shadowing which was at least segmen-
tal or present in one lobe (excluding the bronchi);
bronchopneumonia was defined as inflammation of the
walls of the smaller bronchial tubes, with varying amounts
of pulmonary consolidation due to spread of the inflam-
mation into peribronchiolar alveoli and the alveolar ducts.
Other clinical symptoms were identified by common med-
ical examinations and clinical descriptions.
Real-time polymerase chain reaction (PCR) for detection
of HPIV and other common respiratory pathogens
DNA or RNA from respiratory samples was extracted
using QIAamp DNA Mini Kit or QIAamp Viral RNA
Mini Kit (Qiagen Co. Ltd., Shanghai, China) in accordance
with the manufacturer’s protocols. The four types of HPIV
were tested by TaqMan real-time PCR as previously
reported [19], and 13 other common respiratory patho-
gens were also selected for TaqMan real-time PCR testing,
including influenza A virus (infA), influenza B virus (infB),
respiratory syncytial virus (RSV), adenovirus (ADV), en-
terovirus (EV), human metapneumovirus (HMPV), four
strains of human coronavirus (HCoV-229E, OC43, NL63
and HKU1), human bocavirus (HBoV), Mycoplasma pneu-
moniae (MP), and Chlamydophila pneumoniae (CP) [19].
Statistical analysis
For comparisons of categorical data, χ2 test and Fisher’s
exact test were used where appropriate. All tests were two-
tailed and p<0.05 was considered statistically significant.
Results
Detection of HPIVs from patients with ARTI
We tested 4755 samples for HPIV and 13 other respira-
tory pathogens between July 2009 and August 2011 in
Guangzhou, southern China. The median age was 4.75
(interquartile range, 1.00 to 25.00), and ranged from one
day to 91 years. Pathogens were detected in 2439/4755
(51.3%) samples, and were detected in a higher propor-
tion of samples from children (<14 years old) (1503/
2793; 53.8%) than from adults (≥14 years old) (936/1962;
47.7%) (p<0.001). The pathogens identified most fre-
quently were infA (833/4755; 17.5%), RSV (524/4755;
11.0%) and MP (274/4755; 5.8%) (Table 1).
HPIVs were identified in 178/4755 (3.7%) samples.
Ninety-nine (2.1%) samples were positive for HPIV-3, 58
(1.2%) for HPIV-1, 19 (0.4%) for HPIV-2 and 8 (0.2%)
for HPIV-4 (Table 1). Some samples were positive for
multiple HPIV types, therefore the sum of these seg-
ments is more than 178. The age of patients positive for
HPIV ranged from one month to 78 years. The male to
female ratio was 139:39 in HPIV-positive patients and
2759:1818 in HPIV-negative patients (p<0.001). The
child to adult ratio was 162:12 in HPIV-positive patients
and 2627:1950 in HPIV-negative patients (p<0.001). The
distribution and co-infection status of HPIV-positive
patients are shown in Figure 1 according to different age
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Table 1 Detection of respiratory pathogens by real-time PCR
Pathogens# Number of positive samples with potential pathogens* Detection rate (%)
HPIV-1 HPIV-2 HPIV-3 HPIV-4 infA infB RSV ADV HMPV HBoV EV 229E OC43 NL63 HKU1 MP CP
HPIV-1 58 2 2 0 3 0 6 0 0 3 6 1 3 1 0 6 0 1.2
HPIV-2 19 2 0 1 0 6 0 1 0 1 2 3 0 0 2 0 0.4
HPIV-3 99 0 4 3 5 2 2 5 5 0 4 1 0 9 0 2.1
HPIV-4 8 0 0 1 1 0 0 1 0 0 0 0 1 0 0.2
infA 833 9 28 9 5 6 17 6 14 2 5 16 0 17.5
infB 201 4 0 5 1 5 0 0 0 0 4 0 4.2
RSV 524 11 7 8 44 6 3 5 1 13 1 11.0
ADV 151 3 4 10 4 4 4 1 5 0 3.2
HMPV 164 2 7 2 4 1 0 5 0 3.4
HBoV 103 7 0 3 1 3 10 0 2.2
EV 226 3 6 5 0 9 0 4.8
229E 35 6 2 0 1 0 0.7
OC43 88 2 0 6 0 1.9
NL63 33 0 1 1 0.7
HKU1 20 5 0 0.4
MP 274 0 5.8
CP 7 0.1
1 pathogen 35 7 66 4 726 171 392 107 125 57 124 13 43 14 8 196 5 44.0
2 pathogens 18 8 23 4 92 29 104 31 33 32 80 15 30 13 9 65 2 12.4
≥3 pathogens 5 4 10 0 15 1 28 13 6 14 22 7 15 6 3 13 0 3.4
#HPIV: human parainfluenza virus, infA: influenza A virus, infB: influenza B virus, RSV: respiratory syncytial virus, ADV: adenovirus, HMPV: human metapneumovirus, HBoV: human bocavirus, EV: enterovirus, 229E: human
coronavirus 229E, OC43: human coronavirus OC43, NL63: human coronavirus NL63, HKU1: human coronavirus HKU1, MP: Mycoplasma pneumoniae, and CP: Chlamydophila pneumoniae.



















groups. The large majority (160/178; 88.9%) of HPIV-
positive samples were from paediatric patients younger
than 5 years old (Figure 1), but no infant under one
month of age was HPIV positive.
HPIV-3 was isolated from patients aged one month to
78 years. HPIV-3 was isolated predominantly from
patients under 5 years of age, and the highest frequency
was found in those aged 7–12 months (27/406; 6.7%).
HPIV-1 was isolated from patients aged one month to
47 years, and HPIV-2 was isolated from patients aged
2 months to 41 years old. HPIV-1-positive patients were
more evenly distributed across ages than HPIV-3-positive
patients, but like HPIV-3 the highest frequency of HPIV-1
was detected from patients aged 7–12 months (9/406;
2.2%). HPIV-2 was not isolated as frequently as HPIV-3 or
HPIV-1, but the highest frequencies of HPIV-2 were found
in patients’ age groups of 0–3 months (4/316; 1.3%) and
4–6 months (3/274; 1.1%). Only 8 (0.2%) patients were
HPIV-4 positive in this study, and patient age ranged from
5 months to 8 years.
66 of 178 (37.1%) HPIVs-positive-patients were co-
infected with other 11/13 concerned pathogens except
HCoV-HKU1 and CP. Pathogens with the highest fre-
quency of co-infection with HPIV were RSV (18/66; 27.3%)
and MP (18/66; 27.3%), followed by EV (13/66; 19.7%) and
HCoV-OC43 (10/66; 15.2%) (Table 1). The vast majority of
co-infections were in children (64/66; 97.0%), especially in
patients under 5 years of age (63/66; 95.5%) (Figure 1). The
co-infection rate of HPIV-2 was 63.2% (12/19), the rate
of HPIV-4 was 50% (4/8) the rate of HPIV-1 was 39.7%
(23/58) and the rate of HPIV-3 was 33.3% (33/99) (Table 1).
Seasonal distribution of HPIVs
In general, detection of HPIVs increased as autumn turned
to winter (September 2009 to November 2009; September
2010 to October 2010) and summer turned to autumn
(April 2011 to July 2011). HPIV-3 and HPIV-1, the two
most frequently isolated types, predominantly drove these
seasonal trends. HPIV-2 and HPIV-4 had different seasonal
patterns, and were mainly isolated as winter turned to
spring (December 2010 to March 2011) (Figure 2).
Clinical characteristics of HPIV-positive patients
4447 of 4755 (93.5%) patients, and 174 of 178 (97.8%)
HPIVs-positive patients’ clinical presentations were ana-
lyzed. Patients with incomplete clinical data available were
excluded from the clinical data analysis. We compared the
clinical characteristics of HPIV-positive to HPIV-negative
patients, characteristics of each of the HPIV types, and
characteristics of single HPIV infections to co-infections
(Table 2).
Significant differences were seen between HPIV-positive
and HPIV-negative patients for pharyngeal discomfort
(p<0.001), hoarseness (p=0.015), “Abnormal pulmonary
breathing sound” (p<0.001), “Dyspnoea” (p<0.001), “Pneu-
monia” (p=0.01), and “Diarrhoea” (p<0.001) (Table 2). In
HPIV-positive samples, the proportion of patients with
“Bronchopneumonia” was 13.8% (24/174) and the propor-
tion with “Increasing lung marking” was 5.7% (10/174), al-
though these proportions were not significantly different
from HPIV-negative patients (p=0.079 and 0.056). HPIV-
positive patients were less likely than HPIV-negative patients
Figure 1 Distribution of HPIV-positive patients among different age groups. *Total number of patients of each age group. †Type of HPIV.
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Figure 2 Seasonal distribution of the four HPIV types from July 2009 to August 2011.
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Table 2 Clinical characteristics of participants


















Nasal obstruction 55(31.6) 1324(31.0) 0.862 20(35.1) 4(22.2) 31(32) 3(37.5) 0.767 34(31.2) 21(32.3) 0.878
Coryza 68(39.1) 1568(36.7) 0.523 22(38.6) 7(38.9) 44(45.4) 1(12.5) 0.306 47(43.1) 21(32.3) 0.157
Sneeze 10(5.7) 221(5.2) 0.738 1(1.8) 1(5.6) 7(7.2) 1(12.5) 0.421 7(6.4) 3(4.6) 0.964
Cough 164(94.3) 3426(80.2) 0.738 53(93) 17(94.4) 93(95.9) 7(87.5) 0.718 104(95.4) 60(92.3) 0.395
Expectoration 77(44.3) 1739(40.7) 0.35 11(19.3) 9(50) 49(50.5) 1(12.5) <0.001 49(45) 28(43.1) 0.809
Pharyngeal discomfort† 33(19.0) 1428(33.4) <0.001 16(28.1) 5(27.8) 12(12.4) 1(12.5) 0.073 22(20.2) 11(16.9) 0.596
Hoarseness 7(4.0) 68(1.6) 0.015 2(3.5) 1(5.6) 3(3.1) 1(12.5) 0.592 7(6.4) 0(0) 0.037
Abnormal pulmonary
breathing sound‡
68(39.1) 1078(25.2) <0.001 20(35.1) 7(38.9) 40(41.2) 4(50) 0.811 43(39.4) 25(38.5) 0.897
Dyspnoea 70(40.2) 1010(23.6) <0.001 19(33.3) 7(38.9) 44(45.4) 3(37.5) 0.529 45(41.3) 25(38.5) 0.713
Increasing lung markings 10(5.7) 134(3.1) 0.056 4(7) 1(5.6) 4(4.1) 1(12.5) 0.718 6(5.5) 4(6.2) 0.859
Bronchopneumonia 24(13.8) 416(9.7) 0.079 11(19.3) 3(16.7) 10(10.3) 1(12.5) 0.464 17(15.6) 7(10.8) 0.372
Pneumonia 28(16.1) 428(10.0) 0.01 10(17.5) 3(16.7) 17(17.5) 0(0) 0.641 20(18.3) 8(12.3) 0.294
Fever (≥38°C) 97(55.7) 3004(70.3) <0.001 33(57.9) 12(66.7) 53(54.6) 2(25) 0.532 57(52.3) 40(61.5) 0.235
Chill 6(3.4) 893(20.9) <0.001 3(5.3) 0(0) 3(3.1) 0(0) 0.666 4(3.7) 2(3.1) 0.836
Dizziness 4(2.3) 543(12.7) <0.001 3(5.3) 1(5.6) 0(0) 0(0) 0.125 3(2.8) 1(1.5) 0.605
Headache 7(4.0) 1063(24.9) <0.001 4(7) 2(11.1) 1(1) 0(0) 0.092 6(5.5) 1(1.5) 0.198
Myalgia 3(1.7) 613(14.3) <0.001 2(3.5) 1(5.6) 0(0) 0(0) 0.202 3(2.8) 1(1.5) 0.605
Debilitation 6(3.4) 1103(25.8) <0.001 2(3.5) 1(5.6) 3(3.1) 0(0) 0.902 3(2.8) 3(4.6) 0.515
Vomiting 14(8.0) 326(7.6) 0.839 5(8.8) 2(11.1) 9(9.3) 0(0) 0.823 6(5.5) 8(12.3) 0.110
Poor appetite 27(15.5) 737(17.2) 0.553 11(19.3) 2(11.1) 13(13.4) 1(12.5) 0.736 17(15.6) 10(15.4) 0.970
Diarrhoea 16(9.2) 77(1.8) <0.001 3(5.3) 1(5.6) 12(12.4) 0(0) 0.333 11(10.1) 5(7.7) 0.596
Convulsion 2(1.1) 63(1.5) 0.726 1(1.8) 0(0) 1(1) 0(0) 0.916 2(1.8) 0(0) 0.272
Rash etc. 5(2.9) 64(1.5) 0.15 5(8.8) 0(0) 5(5.2) 0(0) 0.443 4(3.7) 1(1.5) 0.416
*Data are No.(%) of each group. Percentages sum to over 100% because some patients had more than one diagnosis.
†Including pharyngeal dryness and pharyngalgia.
‡Including phlegm rale, wheeze rale, bubbling rale, moist rale, and rhonchi.
§Two-tailed χ2 test, testing the distribution of each illness or diagnosis between HPIV-positive and HPIV-negative patients.
※Two-tailed χ2 test, testing the distribution of each illness or diagnosis between the four HPIV types.



















to present with each of the six symptoms of “Systemic
influenza-like symptoms” (p<0.001) (Table 2).
The only significant difference in clinical characteristics
between patients solely infected with HPIV and those co-
infected was “Hoarseness” (p=0.037), present in 7 patients
with “single HPIV” but no co-infected patient (Table 2).
The only significant difference in clinical presentation
between HPIV types was “Expectoration,” in which 49/97
(50.5%) HPIV-3 positive patients, 9/18 (50%) HPIV-2 posi-
tive patients, 11/57 (19.3%) HPIV-1 positive patients and
1/8 (12.5%) HPIV-4 positive patients presented with the
symptom (p<0.001) (Table 2).
Within HPIV-positive patients, 10/10 (100%) adult patients
presented with systemic influenza-like symptoms, while
90/164 (54.9%) paediatric patients presented with these
symptoms (p=0.005).
Discussion
HPIVs are common respiratory pathogens and are im-
portant causes of URTI and LRTI [1,3,8,9]. Previous
studies have predominantly focused on HPIV-1, HPIV-2
and HPIV-3 infection in children because of high posi-
tive rate and morbidity of three types of HPIV infection
in children, therefore less is known about HPIV-4 infec-
tion and HPIV infection in adults [20]. In this study, we
analysed the characteristics of the four HPIV types in
children and adults with ARTI in Guangzhou, southern
China over a 26 month period.
Of the pathogens investigated in this study, HPIVs
were the sixth most frequently isolated. The predomin-
ant types were HPIV-3 and HPIV-1, which is consistent
with previous reports [5-7]. HPIVs were isolated with
higher frequency from males than females, similar to the
previous study [21]. Immunity to HPIVs is incomplete,
and infections occur throughout life [20]. In this study,
HPIVs were detected in patients over a wide age distri-
bution. However, many more children were infected
than adults (p<0.001), and the vast majority of HPIV
infections occurred in patients under 5 years of age. The
four HPIV types differed in age distribution of patients
infected. HPIV-3 was mainly detected in paediatric patients
under 3 years old, while HPIV-1 and HPIV-2 were isolated
from a broader age distribution than HPIV-3 (Figure 1).
No infant under one month of age was HPIV positive.
These results are in accordance with seroprevalence stud-
ies indicating that newborn infants have high levels of
HPIV antibodies, and that these levels decrease substan-
tially by 7 to 12 months of age [20]. In this study, HPIV-4
was only detected in children (4 months to 8 years old).
This result is different from previous studies in which fairly
equal infection rates were reported among infants younger
than one year old, preschool children, school age children
and adults [14-18]. The low HPIV-4 positivity in our study
may have influenced our results.
Co-infection of HPIV with other respiratory pathogens
was common for all four HPIV types, similar to previous
reports [20-22]. RSV, MP, EV and HCoV-OC43 were the
main co-detected pathogens in this study. Co-infections
were mostly found in children, especially in patients under
5 years of age (Figure 1). This might indicate that imma-
ture immune systems of children leave them susceptive to
potential pathogens. However, no significant differences in
clinical presentation were seen between patients solely
infected with HPIV and patients co-infected with HPIV
and other respiratory pathogens (Table 2).
Biennial fall epidemics of HPIV-1 have been reported in
previous studies [2,7,13,23]. HPIV-2 has been reported to
cause infections biennially with HPIV-1, to alternate years
with HPIV-1, or to cause yearly outbreaks [7,24,25]. HPIV-3
is reported to have occurred annually during April to June
in the United States [2]. Only a small number of studies
have studied the epidemiology of HPIV-4, and the num-
bers of infections were too low to clearly identify seasonal
peaks in activity [2,14-18]. In this study, HPIVs were iso-
lated throughout the year. Seasonal peaks of HPIVs, driven
mostly by HPIV-3 and HPIV-1, occurred in the time when
autumn turned to winter and summer turned to autumn
(September 2009 to November 2009; September 2010 to
October 2010; April 2011 to July 2011). These results dif-
fer from previous reports [2,7,13,23]. In addition, HPIV-3
and HPIV-1 did not show the competitive interaction
described previously, where HPIV-3 activity appeared to
be greater during years when HPIV-1 was not circulating
[2]. The different geographic location might lead to the
different seasonal distributions of HPIVs. HPIV-2 and
HPIV-4 were not isolated as frequently as HPIV-3 and
HPIV-1, and the seasonal peak of HPIV-2 and HPIV-4
was in the turn of winter to spring (December 2010 to
March 2011). The frequency of detection of these two
HPIV types increased when detection of HPIV-3 and
HPIV-1 declined.
HPIVs can cause a spectrum of respiratory illness, and
more “hoarseness” (p=0.015), “abnormal pulmonary breathing
sound” (p<0.001), “dyspnoea” (p<0.001), and “pneumonia”
(p=0.01) presented in HPIV-positive patients than HPIV-
negative patients. In our study, more “diarrhoea” (p<0.001)
presented in HPIV-positive patients than HPIV-negative
patients suggesting pathogenic activity of HPIV in gastro-
intestinal illness (Table 2). Systemic influenza-like symptoms
were not main presentations of HPIV-positive patients over-
all (Table 2), but HPIV-positive adult patients presented
with significantly more systemic influenza-like symptoms
than HPIV-positive paediatric patients (p=0.005). This re-
sult suggests that the clinical presentation of HPIV infec-
tion may differ by patient age as previously shown for
HBoV [19].
The relationship between HPIV infection and neurologic
disease has been studied for many decades. In a previous
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report, children hospitalized with HPIVs had serious febrile
seizures [25]. In contrast, we found no significant differ-
ence in convulsion between HPIV-positive and HPIV-
negative patients (p=0.726).
This study investigated presentations of the four HPIV
types and attempted to distinguish between different types
of HPIVs by clinical presentation. However, because all
four HPIV types caused a wide spectrum of symptoms,
distinguishing HPIV types by clinical characteristics alone
was not possible as the previous study [26].
Conclusions
HPIV infection led to a wide spectrum of symptoms, and
LRTI was the significant presentation. Similar clinical man-
ifestations were found in the patients with four different
types of HPIVs. More diarrhoea found in HPIV-positive
than HPIV-negative patients suggested pathogenic activity
of HPIV in gastrointestinal illness. All 10 adults HPIV-
positive patients suffered from systemic influenza-like
symptoms suggested that the clinical presentation of HPIV
infection may differ by patient age. Co-infections were
common for the four HPIV types. However, no significant
differences were seen in clinical presentation between
patients solely infected with HPIV and patients co-infected
with HPIV and other respiratory pathogens.
This study explored characteristics of the four HPIV
types and provided novel insights into the epidemiology
and clinical implications of HPIVs.
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